September 2026– date –
-
Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers
News-Medical UK Overview Researchers have discovered that the mechanism by which cancer-driving proteins accumulate within tumors significantly influences the efficacy of PROTAC drugs. The study demonstrated that PROTACs are more effecti... -
The Multispecific Antibody Revolution: Reshaping CDMOs for Next-Gen Biologics
BioSpace USA Overview The rapid advancement of multispecific antibody therapeutics is fundamentally transforming the service delivery models and development architectures of Contract Development and Manufacturing Organizations (CDMOs). T... -
UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs
UBC Medicine Canada Overview The University of British Columbia's Faculty of Medicine has appointed three world-renowned scientists as Eddie Goldenberg Research Chairs to accelerate breakthroughs in AI-driven protein design, drug deliver... -
Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance
Fierce Biotech USA Overview Roche's Genentech has announced a significant collaboration with DualityBio, a deal potentially exceeding $1 billion, aimed at developing next-generation Antibody-Drug Conjugates (ADCs). This partnership will ... -
Polymeric Nanoparticles Unlock New Frontiers in Drug Delivery, Gene Therapy, and Medical Imaging
Nanbiosis Spain Overview Polymeric nanoparticles are emerging as a highly versatile and promising platform in nanomedicine, poised to revolutionize areas such as drug delivery, gene therapy, and medical imaging. Their customizable nature... -
Logic-Gated Bispecific ADCs Break Toxicity Barrier, Unleash Thousands of New Cancer Targets
Drug Discovery News USA Overview A novel logic-gated platform for bispecific antibody-drug conjugates (bsADCs) shows promise in unlocking thousands of previously inaccessible cancer targets for therapeutic development. By simultaneously ... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
Smart Hydrogel-Nanoparticle Platforms Pioneer Precision Drug Delivery and TME Modulation in Breast Cancer
ACS Publications USA Overview A recent paper in ACS Publications unveils a smart hydrogel-nanoparticle platform poised to revolutionize breast cancer treatment through precise drug delivery and tumor microenvironment (TME) modulation. Th... -
AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment
Fierce Biotech USA Overview AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, ... -
Democratizing Advanced Immunotherapy: BiTE Therapies Expand into Community Cancer Centers
American Oncology Network USA Overview Bispecific T-cell Engager (BiTE) therapy represents a significant breakthrough in cancer treatment, now experiencing expanding adoption within community oncology facilities across the United States....
